Pathogenic role of Fgf23 in Hyp mice
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Inactivating mutations of the PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) endopeptidase, the disease-causing gene in X-linked hypophosphatemia (XLH), results in increased circulating levels of fibroblastic growth factor-23 (FGF23), a bone-derived phosphaturic factor. To determine the causal role of FGF23 in XLH, we generated a combined Fgf23-deficient enhanced green fluorescent protein (eGFP) reporter and Phex-deficient Hyp mouse model ( Fgf23+/−/ Hyp). eGFP expression was expressed in osteocytes embedded in bone that exhibited marked upregulation of eGFP in response to Phex deficiency and in CD31-positive cells in bone marrow venules that expressed low eGFP levels independently of Phex. In bone marrow stromal cells (BMSCs) derived from Fgf23−/−/ Hyp mice, eGFP expression was also selectively increased in osteocyte-like cells within mineralization nodules and detected in low levels in CD31-positive cells. Surprisingly, eGFP expression was not increased in cell surface osteoblasts, indicating that Phex deficiency is necessary but not sufficient for increased Fgf23 expression in the osteoblast lineage. Additional factors, associated with either osteocyte differentiation and/or extracellular matrix, are necessary for Phex deficiency to stimulate Fgf23 gene transcription in bone. Regardless, the deletion of Fgf23 from Hyp mice reversed the hypophosphatemia, abnormal 1,25(OH)2 D 3 levels, rickets, and osteomalacia associated with Phex deficiency. These results suggest that Fgf23 acts downstream of Phex to cause both the renal and bone phenotypes in Hyp mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Francis, F., Hennig, S., Korn, B., Reinhardt, R., de Jong, P., Poustka, A., Lehrach, H., Rowe, P. S. N., Goulding, J. N., Summerfield, T., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-130 · Cited by 1,107
Yamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 671
Murshed, M., Harmey, D., Millán, J. L., McKee, M. D., & Karsenty, G. (2005) · Genes & Development · doi:10.1101/gad.1276205 · Cited by 601
Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., J+APw-ppner, H., & Lanske, B. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.09.007 · Cited by 542
Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX
Liu, S., Guo, R., Simpson, L. G., Xiao, Z.-S., Burnham, C. E., & Quarles, L. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304544200 · Cited by 508
Self-citationLarsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, Ö., Tenenhouse, H. S., Jüppner, H., & Jonsson, K. B. (2004) · Endocrinology · doi:10.1210/en.2003-1768 · Cited by 499
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
White, K. E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T. M., & Econs, M. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00064.x · Cited by 493
Cited by
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
“Dmp1 null mice have a similar phenotype to Hypmice carrying a Phex mutation, that of osteomalacia and rickets owing to elevated FGF-23 levels in osteocytes.((64,65)) Both Dmp1 and Phex appear to downregulate FGF-23 expression, which, in turn, allows reabsorption of phosphate by the kidney, thereby maintaining sufficie…”
BackgroundFeng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199
Self-citationThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & Ikeda, K. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.001 · Cited by 848
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
The Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707
Regulation and Function of the FGF23/Klotho Endocrine Pathways
Martin, A., David, V., & Quarles, L. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00002.2011 · Cited by 594
Self-citationMaternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery
Kovacs, C. S. (2016) · Physiological Reviews · doi:10.1152/physrev.00027.2015 · Cited by 544
Mechanosensation and transduction in osteocytes
Klein-Nulend, J., Bakker, A. D., Bacabac, R. G., Vatsa, A., & Weinbaum, S. (2013) · Bone · doi:10.1016/j.bone.2012.10.013 · Cited by 528
Osteocytes: master orchestrators of bone
Schaffler, M. B., Cheung, W.-Y., Majeska, R., & Kennedy, O. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9790-y · Cited by 514
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Haffner, D., Emma, F., Eastwood, D. M., Biosse Duplan, M., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 521
Endocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459
Self-citationPhosphate homeostasis and its role in bone health
Penido, M. G. M. G., & Alon, U. S. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2175-z · Cited by 445
Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M. L., Goetz, R., Mohammadi, M., & Baum, M. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90742.2008 · Cited by 438
Osteocytes as Dynamic Multifunctional Cells
BONEWALD, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 417
How Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 408
Self-citationUpdate on fibroblast growth factor 23 in chronic kidney disease
Wolf, M. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 391
Farrow, E. G., Yu, X., Summers, L. J., Davis, S. I., Fleet, J. C., Allen, M. R., Robling, A. G., Stayrook, K. R., Jideonwo, V., Magers, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110905108 · Cited by 380
Tagliabracci, V. S., Engel, J. L., Wiley, S. E., Xiao, J., Gonzalez, D. J., Nidumanda Appaiah, H., Koller, A., Nizet, V., White, K. E., & Dixon, J. E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402218111 · Cited by 327
Fukumoto, S., & Martin, T. J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.02.001 · Cited by 311
Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease
Quarles, L. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.027 · Cited by 298
Self-citationRole of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models
Su, N., Jin, M., & Chen, L. (2014) · Bone Research · doi:10.1038/boneres.2014.3 · Cited by 290
Mechanosensation and transduction in osteocytes
Bonewald, L. F. (2006) · BoneKEy-Osteovision · doi:10.1138/20060233 · Cited by 283
Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121385 · Cited by 276
Self-citationSkeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
Quarles, L. D. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.218 · Cited by 269
Self-citationOsteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
“Constitutively, the Klotho protein is expressed only in some organs (including the parathyroid gland, kidneys, testicles, ovaries, brain, pituitary gland, and choroids plexuses) [90, 94].”
Komaba, H., Goto, S., Fujii, H., Hamada, Y., Kobayashi, A., Shibuya, K., Tominaga, Y., Otsuki, N., Nibu, K.-I., Nakagawa, K., et al. (2010) · Kidney International · doi:10.1038/ki.2009.414 · Cited by 267
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090509 · Cited by 265
Nakatani, T., Sarraj, B., Ohnishi, M., Densmore, M. J., Taguchi, T., Goetz, R., Mohammadi, M., Lanske, B., & Razzaque, M. S. (2009) · The FASEB Journal · doi:10.1096/fj.08-114397 · Cited by 255
Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., & Quarles, L. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-177816 · Cited by 254
“The Fgf23-eGFP reporter and Dmp1-null mice were created as described previously (28, 33).”
BackgroundMethodResultInfluentialSelf-citationOverview of the FGF23-Klotho axis
Kuro-o, M. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1260-4 · Cited by 162
“Hyp mice, which have deletions in the Phex gene, show high FGF23 expression in the bone, high serum levels of FGF23, hypophosphatemia, and impaired bone mineralization, as observed in XLH patients [17, 18].”
BackgroundStubbs, J., Liu, S., & Quarles, L. D. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00308.x · Cited by 123
“FGF23 and 1,25(OH)2D3 are involved in a feedback loop, with 1,25(OH)2D3 increasing circulating FGF23 levels which, in turn, suppress 1,25(OH)2D3 production, (9,12,23,31,32) Under conditions of excess 1,25(OH)2D3, the increases in GI calcium and phosphate absorption and loss of phosphaturic actions due to suppressed PT…”
BackgroundSelf-citationPhosphate-sensing and regulatory mechanism of FGF23 production
Takashi, Y., & Fukumoto, S. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01205-9 · Cited by 42
Physiopathology of Phosphate Disorders
Portales-Castillo, I., Rieg, T., Khalid, S. B., Nigwekar, S. U., & Neyra, J. A. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.011 · Cited by 26
Uda, Y., Saini, V., Petty, C. A., Alshehri, M., Shi, C., Spatz, J. M., Santos, R., Newell, C. M., Huang, T. Y., Kochen, A., et al. (2021) · Aging · doi:10.18632/aging.203808 · Cited by 20
FGF23 in chronic kidney disease: Bridging the heart and anemia
Figurek, A., Rroji, M., & Spasovski, G. (2023) · Cells · doi:10.3390/cells12040609 · Cited by 22
“It is interesting to note that administering Ang II to rodents increased the ectopic expression of FGF23 in the heart, a tissue that typically does not express FGF23 or Klotho in physiological amounts [39,40], as well as the expression of the FGF23 in bone, the physiological site of FGF23 production.”
BackgroundTargeting aging with the healthy skeletal system: The endocrine role of bone
Zheng, X.-Q., Lin, J.-L., Huang, J., Wu, T., & Song, C.-L. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09812-6 · Cited by 19
“Animal experiments have reported that both transgenic FGF23 excess [20, 21] and global FGF23-KO mouse models [22, 23] have severe endocrine disorders, skeletal malformations, fertility disorders, and shortened life span.”
BackgroundYashiro, M., Ohya, M., Mima, T., Nakashima, Y., Kawakami, K., Yamamoto, S., Kobayashi, S., Yano, T., Tanaka, Y., Sonou, T., et al. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113139 · Cited by 18
Yuan, Y., Jagga, S., Martins, J. S., Rana, R., Pajevic, P. D., & Liu, E. S. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252348 · Cited by 17
Metadata
- Authors
- Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D. W., & Quarles, L. D.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2006-07
- Volume
- 291
- Issue
- 1
- Pages
- E38-E49
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2152109784
- Cited by
- 495
- References
- 35
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.